Johnson & Johnson (JNJ)

JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.

WASHINGTON--(BUSINESS WIRE)--The Association of Medical Device Reprocessors (AMDR) announced that Judge James Selna of the U.S. District Court for the Central District of California has issued a perma...

Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.

JPM, GS, JNJ, DIS, and MSFT are five blue-chip stocks that stand out with strong growth drivers and upgraded estimates as the Dow hits record highs.

Johnson & Johnson's NYSE: JNJ stock chart is sending a clear signal that contrasts sharply with the persistent hum of repetitive negative headlines. While news cycles continue to circle long-running l...

Dividend investing can be tricky, since income-focused investors want to find high yields while also avoiding stocks that end up cutting their quarterly payouts. There's a balance that has to be found...

Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued...

Dividend stocks aren't all created equal. Some decrease their payouts, or suspend them altogether, when they face headwinds.

It's a move to boost its domestic production as President Donald Trump threatens to slap devastating tariffs on pharmaceutical imports.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?